Matthew Wakefield

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer

Ana C Veneziani, Clare Scott, Matthew J Wakefield, Anna V Tinker, Stephanie Lheureux

Journal article  |  2023  |  THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer...

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

Nicola S Meagher, Kylie L Gorringe, Matthew Wakefield, Adelyn Bolithon, Chi Nam Ignatius Pang, Derek S Chiu, Michael S Anglesio, Kylie-Ann Mallitt, Jennifer A Doherty, Holly R Harris, Joellen M Schildkraut, Andrew Berchuck, Kara L Cushing-Haugen, Ksenia Chezar, Angela Chou, Adeline Tan, Jennifer Alsop, Ellen Barlow, Matthias W Beckmann, Jessica Boros, et al.

Journal article  |  2022  |  CLINICAL CANCER RESEARCH

PURPOSE: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid ..

Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

Gwo Yaw Ho, Elizabeth L Kyran, Justin Bedo, Matthew J Wakefield, Darren P Ennis, Hasan B Mirza, Cassandra J Vandenberg, Elizabeth Lieschke, Andrew Farrell, Anthony Hadla, Ratana Lim, Genevieve Dall, James E Vince, Ngee Kiat Chua, Olga Kondrashova, Rosanna Upstill-Goddard, Ulla-Maja Bailey, Suzanne Dowson, Patricia Roxburgh, Rosalind M Glasspool, et al.

Journal article  |  2022  |  CANCER RESEARCH

UNLABELLED: Ovarian carcinosarcoma (OCS) is an aggressive and rare tumor type with limited treatment options. OCS is hypothesized ..

Delivering personalized care and research for rare cancers in the increasingly genomic world?

Clare L Scott, Ratana Lim, Damien Kee, Chloe Georgiou, Reece Caldwell, Lia Papadopoulos, Michael S Krasovitsky, Rebecca Tay, Alison Bourne, Cassandra Vandenberg, Genevieve Dall, Kristy Shield-Artin, Amandine Carmagnac, Gayanie Ratnayak, Joshua Tram, Warren Zhou, Justin Bedo, Jocelyn Penington, Layla Zhu, Joseph Vissers, et al.

Conference Proceedings  |  2021  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

Ksenija Nesic, Olga Kondrashova, Rachel M Hurley, Cordelia D McGehee, Cassandra J Vandenberg, Gwo-Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield-Artin, Marc Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, Anna DeFazio, et al.

Journal article  |  2021  |  CANCER RESEARCH

In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene RAD51C are established drivers of defectiv..

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

Rachel M Hurley, Cordelia D McGehee, Ksenija Nesic, Cristina Correia, Taylor M Weiskittel, Rebecca L Kelly, Annapoorna Venkatachalam, Xiaonan Hou, Nicholas M Pathoulas, X Wei Meng, Olga Kondrashova, Marc R Radke, Paula A Schneider, Karen S Flatten, Kevin L Peterson, Marc A Becker, Ee Ming Wong, Melissa S Southey, Alexander Dobrovic, Kevin K Lin, et al.

Journal article  |  2021  |  NAR CANCER

Acquired PARP inhibitor (PARPi) resistance in BRCA1- or BRCA2-mutant ovarian cancer often results from secondary mutations that re..

Abstract 1074: Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma

Cassandra J Vandenberg, Gwo-Yaw Ho, Ksenija Nesic, Elizabeth M Swisher, Sean M Grimmond, Matthew J Wakefield, Holly E Barker, David D Bowtell, Clare L Scott

Conference Proceedings  |  2021  |  Cancer Research

Abstract The high mortality (>80%) seen in high-grade serous ovarian cancer (HGSOC) highlights the unmet clinica..

BRCA1 D11q isoform expression impacts PARP inhibitor responses in high grade serous ovarian carcinoma patient derived xenografts.

Ksenija Nesic, Cassandra J Vandenberg, Olga Kondrashova, John J Krais, Neil Johnson, Elizabeth M Swisher, Matthew J Wakefield, Clare L Scott

Conference Proceedings  |  2021  |  CANCER RESEARCH

Chaperone-mediated protein degradation (CHAMP): A novel technology for tumor-targeted protein degradation.

Cassandra J Vandenberg, Gwo-Yaw Ho, Ksenija Nesic, Elizabeth M Swisher, Sean M Grimmond, Matthew J Wakefield, Holly E Barker, David D Bowtell, Clare L Scott

Conference Proceedings  |  2021  |  CANCER RESEARCH

Abstract 2057: BRCA1 D11q isoform expression impacts PARP inhibitor responses in high grade serous ovarian carcinoma patient derived xenografts

Ksenija Nesic, Cassandra J Vandenberg, Olga Kondrashova, John J Krais, Neil Johnson, Elizabeth M Swisher, Matthew J Wakefield, Clare L Scott

Conference Proceedings  |  2021  |  Cancer Research

Abstract Background: Acquired PARP inhibitor (PARPi) resistance in High Grade Serous Ovarian Carcinoma (HGSOC) comm..